title: Intravitreal bevacizumab for branch retinal vein occlusion.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Spandau
authors.forename: Anne
authors.initials: A
authors.lastname: Wickenhäuser
authors.forename: Florian
authors.initials: F
authors.lastname: Rensch
authors.forename: Jost
authors.initials: J
authors.lastname: Jonas
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab